PDF
(Download)
|
- Saw Palmetto (Serenoa repens)
- Lower Urinary Tract Symptoms
- Benign Prostatic Hyperplasia
- Tamsulosin
|
Date:
12-15-2014 | HC# 071422-510
|
Re: Saw Palmetto Berry Extract Alone Is as Effective in Treating Benign Prostatic Hyperplasia as Tamsulosin
Argirović A,
Argirović D. Does the addition
of Serenoa repens to tamsulosin
improve its therapeutical efficacy in benign prostatic hyperplasia? Vojnosanit Pregl. December
2013;70(12):1091-1096.
Lower urinary tract symptoms (LUTS) are associated
with benign prostatic hyperplasia (BPH), and the incidence of both LUTS and BPH
increase in men over the age of 50. The severity of LUTS is, in part,
determined by smooth muscle tone of the prostate and bladder neck.
Alpha-blockers (ABs) and α-reductase
inhibitors (5-ARIs) are thought to improve the functioning of the smooth
muscles and both have been used to treat LUTS/BPH. Tamsulosin is an AB that
seems to be more effective at targeting the smooth muscle of the prostate and
bladder neck than other ABs, and thus, is commonly used to treat LUTS/BPH. Saw
palmetto (Serenoa repens) has been
used as an alternative treatment for LUTS/BPH. The goal of this 3-armed, randomized
study was to compare the effectiveness of tamsulosin and saw palmetto alone
versus a combination of tamsulosin and saw palmetto in treating men with BPH.
Two hundred ninety-seven men with BPH who were between
the ages of 50 and 87 years old were recruited for this 6-month study conducted
in Belgrade, Serbia. Patients had to be at least 50 years old, have a total
International Prostate Symptom Score (IPSS) between 7 and 18 points, a Quality
of Life score (QoLs) greater than 3, a maximal urine flow (Qmax) between 5 and
15 ml/s, a post-voiding residual volume (PVR) < 150 ml, a prostate volume
(PV) of < 50 ml, and serum prostate-specific antigen (PSA) between 1.5 and 4
ng/ml. Patients were excluded if they had bladder or prostate cancer, bladder
stones, a history of bladder disease or infection, neurogenic lower urinary
tract dysfunction, or other diseases which can cause urinary problems. Patients
were randomly divided into 1 of 3 treatment groups: a group that took
tamsulosin (0.4 mg/day) alone; a group that took saw palmetto (Prostamol® Uno, 320 mg/day berry; Berlin-Chemie Menarini; Berlin, Germany) alone; or
a group that took both tamsulosin (0.4 mg/day) and saw palmetto (320 mg/day). Prostamol
Uno contains 320 mg of saw palmetto berry extract (no standardization
information) plus succinylated
gelatin, glycerol, purified water, titanium dioxide (E171), black iron oxide
(E172), and cochineal red (E124). The
study did not cite the randomization technique, and did not include information
about blinding. The following information was collected prior to treatment: a
complete medical history, a list of current medications, a physical exam, urine
analysis, urine culture, creatinine, PSA, total IPSS, QoLs, PV, Qmax, and PVR.
IPSS, QoLs, Qmax, and PVR were measured again at 3 and 6 months. PV and PSA
were re-measured at 6 months. Patients who showed no improvement at 3 months
were removed from the study. Data were analyzed with the Kruskal-Wallis test
and Wilcoxon signed-rank test.
The average age of patients was 64.9 years old, and
there were no differences among treatment groups at pretreatment, although
differences among treatment groups for PV approached significance (P = 0.07).
There were 87 patients in the tamsulosin treatment group, 97 patients in the
saw palmetto treatment group, and 81 patients in the tamsulosin/saw palmetto
treatment group. Patients were lost in each group due to voluntary withdrawal,
protocol violations, lack of efficacy, and loss to follow-up. IPSS decreased
significantly in all groups (P < 0.05), with no significant differences
among groups. The greatest improvement in IPSS was seen in men with pronounced
ejaculation disorders. Qmax increased significantly in all groups over the 6
months of the study (P < 0.005). The percentage of patients affected by
urinary symptoms decreased by over 50% over the course of the study (P <
0.001). QoLs, PV, and PSA all decreased in the treatment groups, but none of
these decreases were significant. The most common adverse effects were
decreased or absent ejaculation and headache. These effects were found only in
the groups that took tamsulosin and tamsulosin plus saw palmetto.
This study provides evidence that saw palmetto is as
effective as tamsulosin in reducing LUTS/BPH, and that the combination of saw
palmetto and tamsulosin is no more effective than either treatment alone for
LUTS/BPH. In addition, both tamsulosin treatment groups had adverse effects,
while no adverse events were found in patients receiving only saw palmetto
extract. Based on this study, it would seem reasonable to treat patients with LUTS/BPH
with saw palmetto alone because of its similar efficacy to tamsulosin and the lack
of adverse side effects. This study lacked a placebo group, and it is therefore
impossible to subtract a placebo effect from the treatment effects. Other
limitations of this study are the relatively short follow-up and lack of
description of treatment blinding.
–Cheryl
McCutchan, PhD
|